Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

CRISPR's off-target problem just got a powerful new watchdog. Salk Institute researchers have developed Superb-seq, a method that maps all CRISPR edits — both intended and accidental — at the level of individual cells. Published in Nature Methods, the tool could make gene-editing therapies safer and more precise by revealing not just where unwanted edits occur, but how they affect cell behavior.
CRISPR gene editing has revolutionized medicine, but it comes with a catch: the molecular scissors sometimes cut in the wrong places. Now, Salk Institute scientists have developed Superb-seq, a groundbreaking method that detects all CRISPR edits — on- and off-target — and tracks how those edits alter gene activity, all at single-cell resolution. The study was published in Nature Methods on November 16, 2026.
Unlike existing tools that can only locate unwanted edits without revealing which cells are affected or how cell behavior changes, Superb-seq integrates Cas9 editing, a short edit-reporting DNA sequence, and single-cell RNA sequencing. When tested on 34,000 cells, it uncovered 43 edit sites in just 10,000 human leukemia cells — 36 of which were off-target — a frequency that surprised even the researchers.
By the Numbers:
Why it matters: Off-target CRISPR edits can disrupt genes that guard against cancer or other diseases. Superb-seq gives researchers and clinicians a clearer safety picture — from early drug development to personalized gene therapies — and could also improve AI models that predict how cells respond to genetic changes.